logo-loader
viewArca Biopharma Inc

Arca Biopharma progresses toward FDA approval of Gencaro as it beats 1Q expectations

Gencaro, a beta blocker designed to treat irregular heartbeat, received a Special Protocol Assessment from the Food and Drug Administration

Heart and stethoscope
The biopharmaceutical company reported a net loss of $1.86 per share, compared to a $3.61 loss in the prior year quarter

Arca biopharma Inc (NASDAQ:ABIO) posted a smaller-than-expected first-quarter loss as its lead drug progressed toward regulatory approval, the company announced Wednesday.

The biopharmaceutical company reported a net loss of $1.86 per share, compared to a $3.61 loss in the prior year quarter. That beat Street expectations of a $1.98 loss.

Cash and its equivalents increased to $8 million from $6.6 million last quarter.

READ: Arca Biopharma rockets after ‘encouraging’ data for beta-blocker Gencaro

Gencaro, its beta blocker designed to treat irregular heartbeat, received a Special Protocol Assessment from the Food and Drug Administration in February. That means its planned 2019 Phase 3 trial will be acceptable to secure FDA approval.

The Colorado-based company also plans to begin non-clinical studies later this year of AB171, a genetically-targeted treatment for heart failure and peripheral arterial disease.

After jumping 10% at the open, the stock fell back to earth, dropping 0.5% to $15.03.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Arca Biopharma Inc

Price: 3.81 USD

NYSE:ABIO
Market: NYSE
Market Cap: $6.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Covid Technologies looking for large growth after being...

Micron Waste Technologies (CSE: MWM- OTC: MICWF) soon to be subsidiary COVID Technologies President Harvey Sidhu joined Steve Darling from Proactive Vancouver to discuss his company being acquired by Micron. Sidhu discusses his company which makes PPE or personal protective equipment....

12 minutes ago

2 min read